STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

Their data suggests that tweaking the expression of FDX2 could make up for the loss of frataxin, the protein tied to FA's development.

By manipulating this pathway, scientists may be able to tweak the immune response to treat cancers, autoimmune disorders, and more.

AIphafold helps make the first major inroad to date towards a new and more effective way to fight the monkeypox virus.

In future, a more detailed understanding of the lung microbiome in pneumonia may enable improved diagnostics, prognosis, and therapeutics.